Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Evaluation of the COBAS Amplicor HCMV Monitor for early detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation

Bone Marrow Transplantation volume 38, pages 53–60 (2006)Cite this article

Abstract

Early diagnosis of human cytomegalovirus (HCMV) infection and the introduction of preemptive antiviral therapy have reduced HCMV-related mortality after allogeneic stem cell transplantation. A critical goal remains stratifying risk profiles and minimizing potential harm owing to antiviral overtreatment. We compared the commercially available standardized COBAS Amplicor CMV Monitor (CACM) to an in-house PCR assay, for the monitoring of HCMV infection. Seventy-two patients were surveyed by an in-house PCR of whole blood, quantitative viral load assessment by CACM and virus culture assays in a prospective and a retrospective study. A high concordance between CACM and PCR was documented. The viral load at onset correlated with the peak viral load (Spearman rank correlation R=0.634, P=0.0004). In patients developing HCMV disease, both viral loads were in trend higher (P=0.823, respectively P=0.053), and the viremic episodes longer (P=0.015), as compared to asymptomatically HCMV-infected patients. The serological pre-transplant status was the major risk factor for the development of HCMV disease, showing highest risk for seropositive patients receiving a seronegative graft, whereas donor type (related or unrelated) and graft type (bone marrow or peripheral blood mobilized stem cells) did not have an influence. HCMV infection proved to be a risk factor for the development of non-viral opportunistic infections (P=0.002).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Emmanuel D, Cunningham L, Jules-Elysee K, Brochstein JA, Kernan NA, Laver J et al. Cyomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988; 109: 777–782.

    Article  Google Scholar 

  2. Ljungman P, Aschan J, Lewensohn-Fuchs I, Carlens S, Larsson K, Lonnqvist B et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell recipients. Transplantation 1998; 66: 1330–1334.

    Article  CAS  PubMed  Google Scholar 

  3. Meyers JD, Flournoy N, Thomas ED . Risk factors for cytomegalovirus infection after human bone marrow transplantation. J Infect Dis 1998; 153: 478–488.

    Article  Google Scholar 

  4. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD, Reed EC et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplantation. Ann Intern Med 1988; 109: 783–788.

    Article  CAS  PubMed  Google Scholar 

  5. Goodrich JM, Boeckh M, Bowden R . Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 1994; 19: 287–298.

    Article  CAS  PubMed  Google Scholar 

  6. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD . Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplantation. Ann Int Med 1993; 118: 173–178.

    Article  CAS  PubMed  Google Scholar 

  7. Li CR, Greenberg P, Gilbert MJ, Goodrich JM, Riddell SR . Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971–1979.

    CAS  PubMed  Google Scholar 

  8. Einsele H, Hebart H, Kauffmann-Schneider C, Sinzger C, Jahn G, Bader P et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV-infection. Bone Marrow Transplant 2000; 25: 757–763.

    Article  CAS  PubMed  Google Scholar 

  9. Caliendo AM, Schuurman R, Yen-Lieberman B, Spector SA, Andrsen J, Manjiry R et al. Comparison of quantitative and qualitative PCR assays for cytomegalovirus in plasma. J Clin Microbiol 2001; 39: 1334–1338.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ljungman P, Griffiths P . Definitions of cytomegalovirus infection and disease. In: Michelson S, Plotkin SA (eds). Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Elsevier Science Publishers: Paris, 1993, pp 233–237.

    Google Scholar 

  11. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815–2820.

    CAS  PubMed  Google Scholar 

  12. Einsele H, Steidle M, Vallbracht A, Saal JG, Ehninger G, Muller CA . Early occurrence of HCMV infection after BMT as demonstrated by the PCR technique. Blood 1991; 77: 1104–1110.

    CAS  PubMed  Google Scholar 

  13. Hebart H, Muller C, Loffler J, Jahn G, Einsele H . Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation. Bone Marrow Transplant 1996; 17: 861–868.

    CAS  PubMed  Google Scholar 

  14. Von Muller L, Hampl W, Hinz J, Meisel H, Reip A, Engelmann E et al. High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay. J Clin Microbiol 2002; 40: 2285–2287.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Boivin G, Quirk MR, Kringstad BA, Germain M, Jordan MC . Early effects of ganciclovir therapy on the quantity of cytomegalovirus DNA in leucocytes of immunocompromised patients. Antimicrob Agents Chemother 1997; 41: 860–862.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Saltzman RL, Qiurk MR, Jordan MC . High levels of circulating cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients. J Clin Investig 1992; 90: 1832–1838.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF et al. Early treatment with ganciclivir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601–1607.

    Article  CAS  PubMed  Google Scholar 

  18. Hebart H, Rudolph T, Loeffler J, Middeldorp J, Ljubicic T, Jahn G et al. Evaluation of the NucliSEns CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 181–187.

    Article  CAS  PubMed  Google Scholar 

  19. Hebart H, Wuchter P, Loeffler J, Gscheidle B, Hamprecht K, Sinzger C et al. Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant. Bone Marrow Transplant 2001; 28: 213–218.

    Article  CAS  PubMed  Google Scholar 

  20. Boeckh M, Bowden RA, Gooley T, Myerson D, Corey L . Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients (letter). Blood 1999; 93: 1781–1782.

    CAS  PubMed  Google Scholar 

  21. Einsele H, Ehninger G, Steidle M, Vallbracht A, Muller M, Schmidt H et al. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet 1991; 338: 1170–1172.

    Article  CAS  PubMed  Google Scholar 

  22. Gor D, Sabin C, Prentice HG, Vyas N, Man S, Griffiths PD et al. Longitudinal analysis in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998; 21: 597–605.

    Article  CAS  PubMed  Google Scholar 

  23. Wolf DG, Spector S . Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation 1993; 56: 330–334.

    Article  CAS  PubMed  Google Scholar 

  24. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA . Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063–4071.

    CAS  PubMed  Google Scholar 

  25. Boivin G, Belanger R, Delage R, Beliveau C, Demers C, Goyette N et al. Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the COBAS AMPLICOR CMV MONITOR PCR test after blood and marrow allogeneic transplantation. J Clin Microbiol 2000; 38: 4356–4360.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Flexman J, Kay J, Fonte R, Herrmann R, Gabbay E, Palladino S . Differences between the quantitative antigenemia assay and the Cobas amplicor monitor quantitative PCR assay for detecting the CMV viraemia in bone marrow and solid organ transplant patients. J Med Virol 2001; 64: 275–282.

    Article  CAS  PubMed  Google Scholar 

  27. Piiparinen H, Hockerstedt K, Lappalainen M, Suni J, Lautenschlager I . Monitoring of viral load by quantitative plasma-PCR during active cytomegalovirus infection of individual liver transplant patients. J Clin Microbiol 2002; 40: 2945–2952.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Aitken C, Barrett-Muir W, Millar C, Templeton K, Thomas J, Sheridan F et al. Use of molecular assays in diagnosis and monitoring of cytomegalovirus disease following renal transplantation. J Clin Microbiol 1999; 37: 2804–2807.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Preiser W, Brauninger S, Schwerdtfeger R, Ayliffe U, Garson JA, Brinks NS et al. Evaluation of diagnostic methods for the detection of cytomegalovirus in recipients of allogeneic stem cell transplants. J Clin Virol 2001; 20: 59–70.

    Article  CAS  PubMed  Google Scholar 

  30. Pellegrin I, Garrigue I, Binquet C, Chene G, Neau D, Bonot P et al. Evaluation of new quantitative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patients. J Clin Microbiol 1999; 37: 3124–3132.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Diaz-Mitoma F, Leger C, Miller H, Giulivi A, Frost R, Shaw L et al. Comparison of DNA amplification, mRNA amplification, and DNA hybridization techniques for detection of cytomegalovirus in bone marrow transplant recipients. J Clin Microbiol 2003; 41: 5159–5166.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D et al. Randomized multicenter trial of foscarnet versus ganciclovir for the preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159–1164.

    Article  CAS  PubMed  Google Scholar 

  33. Ordemann R, Naumann R, Geissler G, Kroshinsky F, Bornhauser M, Schwerdtfeger R et al. Foscarnet – an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation? Ann Hematol 2000; 79: 432–436.

    Article  CAS  PubMed  Google Scholar 

  34. Cope AV, Sabin C, Burroughs A, Rolles K, Griffiths PD, Emery VC . Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997; 176: 1484–1490.

    Article  CAS  PubMed  Google Scholar 

  35. Cope AV, Sweny P, Sabin C, Rees L, Griffiths PD, Emery VC . Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. J Med Virol 1997; 52: 200–205.

    Article  CAS  PubMed  Google Scholar 

  36. Fox JC, Kidd IM, Griffiths PD, Sweny P, Emery VC . Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a polymerase chain reaction: correlation with disease. J Gen Virol 1995; 76: 309–319.

    Article  CAS  PubMed  Google Scholar 

  37. Sia IG, Wilson JA, Espy MJ, Paya CV, Smith TF . Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000; 181: 717–720.

    Article  CAS  PubMed  Google Scholar 

  38. Roberts TC, Brennan DC, Buller RS, Gaudreault-Keener M, Schnitzler MA, Sternhell KE et al. Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients. J Infect Dis 1998; 178: 626–635.

    Article  CAS  PubMed  Google Scholar 

  39. Hassan-Walker AF, Kidd IM, Sabin C . Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: relationship with donor/recipient serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG). J Med Virol 1999; 58: 182–187.

    Article  CAS  PubMed  Google Scholar 

  40. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD . Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032–2036.

    Article  CAS  PubMed  Google Scholar 

  41. Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003; 102: 3060–3067.

    Article  CAS  PubMed  Google Scholar 

  42. Junghanss C, Storb R, Maris MB, Carter RA, Sandmaier BM, Maloney DG et al. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. Br J Haematol 2003; 123: 662–670.

    Article  PubMed  Google Scholar 

  43. Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978–1985.

    Article  CAS  PubMed  Google Scholar 

  44. Boeckh M, Nichols WG . The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103: 2003–2008.

    Article  CAS  PubMed  Google Scholar 

  45. Fishman JA . Pneumocystis carinii and parasitic infections in transplantation. Infect Dis Clin N Am 1995; 9: 1005–1044.

    CAS  Google Scholar 

  46. Grow WB, Moreb JS, Roque D, Marion K, Leather H, Reddy V et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29: 15–19.

    Article  CAS  PubMed  Google Scholar 

  47. Hadley S, Karchmer AW . Fungal infections in solid organ transplant recipients. Infect Dis Clin N Am 1995; 9: 1045–1074.

    CAS  Google Scholar 

  48. Husni RN, Gordon SM, Longworth DL, Arroglia A, Stillwell PL, Avery RK et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26: 753–755.

    Article  CAS  PubMed  Google Scholar 

  49. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M . High risk of death due bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary infection. J Infect Dis 2002; 185: 273–282.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, University of Tübingen Medical Center, Tübingen, Germany

    C Lengerke, T Ljubicic, J Loeffler, H Einsele & H Hebart

  2. Institute of Medical Information Processing, Tübingen, Germany

    C Meisner

  3. Department of Medical Virology, University of Tübingen, Tübingen, Germany

    C Sinzger

  4. Department of Molecular Pathology, University of Tübingen, Tübingen, Germany

    C Sinzger

Authors
  1. C Lengerke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Ljubicic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Meisner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Loeffler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Sinzger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Einsele
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H Hebart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Hebart.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lengerke, C., Ljubicic, T., Meisner, C. et al. Evaluation of the COBAS Amplicor HCMV Monitor for early detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant 38, 53–60 (2006). https://doi.org/10.1038/sj.bmt.1705408

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705408

Keywords

This article is cited by

Search

Advanced search

Quick links